Variant rs397516080 details in Genebe, Genetics Data Aggregator

Genes affected

MYBPC3 (HGNC:7551): (myosin binding protein C3) MYBPC3 encodes the cardiac isoform of myosin-binding protein C. Myosin-binding protein C is a myosin-associated protein found in the cross-bridge-bearing zone (C region) of A bands in striated muscle. MYBPC3 is expressed exclusively in heart muscle and is a key regulator of cardiac contraction. Mutations in this gene are a frequent cause of familial hypertrophic cardiomyopathy. [provided by RefSeq, May 2022]

MYBPC3 links:

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 18 ACMG points.

PVS1

Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.

PM2

Very rare variant in population databases, with high coverage;

PP5

Variant 11-47346638-GAA-G is Pathogenic according to our data. Variant chr11-47346638-GAA-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 42801.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-47346638-GAA-G is described in Lovd as [Pathogenic]. Variant chr11-47346638-GAA-G is described in Lovd as [Likely_pathogenic].

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	Protein	UniProt
MYBPC3	NM_000256.3 linkuse as main transcript	c.913_914delTT	p.Phe305fs	frameshift_variant	11/35	ENST00000545968.6	NP_000247.2	Q14896-1A5YM48

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Protein	UniProt
MYBPC3	ENST00000545968.6 linkuse as main transcript	c.913_914delTT	p.Phe305fs	frameshift_variant	11/35	5	NM_000256.3	ENSP00000442795.1	Q14896-1
MYBPC3	ENST00000399249.6 linkuse as main transcript	c.913_914delTT	p.Phe305fs	frameshift_variant	10/34	5		ENSP00000382193.2	A8MXZ9
MYBPC3	ENST00000544791.1 linkuse as main transcript	n.913_914delTT		non_coding_transcript_exon_variant	11/27	5		ENSP00000444259.1	F5GZR4

Frequencies

GnomAD3 genomes

AF:

0.00000664

AC:

AN:

150494

Hom.:

Cov.:

show subpopulations

Gnomad AFR

AF:

0.00

Gnomad AMI

AF:

0.00

Gnomad AMR

AF:

0.00

Gnomad ASJ

AF:

0.00

Gnomad EAS

AF:

0.00

Gnomad SAS

AF:

0.00

Gnomad FIN

AF:

0.00

Gnomad MID

AF:

0.00

Gnomad NFE

AF:

0.0000148

Gnomad OTH

AF:

0.00

GnomAD4 exome

AF:

0.00000164

AC:

AN:

1217482

Hom.:

AF XY:

0.00000327

AC XY:

AN XY:

610872

show subpopulations

Gnomad4 AFR exome

AF:

0.00

Gnomad4 AMR exome

AF:

0.00

Gnomad4 ASJ exome

AF:

0.00

Gnomad4 EAS exome

AF:

0.00

Gnomad4 SAS exome

AF:

0.00

Gnomad4 FIN exome

AF:

0.00

Gnomad4 NFE exome

AF:

0.00000221

Gnomad4 OTH exome

AF:

0.00

GnomAD4 genome

AF:

0.00000664

AC:

AN:

150494

Hom.:

Cov.:

AF XY:

0.0000136

AC XY:

AN XY:

73440

show subpopulations

Gnomad4 AFR

AF:

0.00

Gnomad4 AMR

AF:

0.00

Gnomad4 ASJ

AF:

0.00

Gnomad4 EAS

AF:

0.00

Gnomad4 SAS

AF:

0.00

Gnomad4 FIN

AF:

0.00

Gnomad4 NFE

AF:

0.0000148

Gnomad4 OTH

AF:

0.00

ClinVar

Significance: Pathogenic/Likely pathogenic

Submissions summary: Pathogenic:20

Revision: criteria provided, multiple submitters, no conflicts

LINK: link

Submissions by phenotype

Hypertrophic cardiomyopathy

Pathogenic:6

Pathogenic, no assertion criteria provided	research	Zaffran Lab, Genetics of Cardiac Diseases Laboratory, Marseille Medical Genetics	-	- -
Pathogenic, criteria provided, single submitter	clinical testing	Labcorp Genetics (formerly Invitae), Labcorp	Nov 21, 2023	This sequence change creates a premature translational stop signal (p.Phe305Profs*27) in the MYBPC3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MYBPC3 are known to be pathogenic (PMID: 19574547). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with hypertrophic cardiomyopathy (PMID: 18533079, 25740977, 27532257, 28794111). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 42801). For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, no assertion criteria provided	research	Rampazzo Lab, Human Molecular Genetics Unit, University of Padua	Apr 18, 2017	It is not found in 250 ethnically matched healthy controls (500 chromosomes), in dbSNP , in the 1000 Genomes Project database, in the Exome Variant Server or in the Exome Aggregation Consortium. We identified this mutation in 19 (19.5%) italian HCM patients (14 men and 5 women). Among 79 relatives belonging to 14 families, 45 resulted to be mutation carriers and 29 of them had phenotypical expression of HCM. A shared haplotype was found in all probands carrying the mutation, indicating that a common founder was likely in these families. -
Pathogenic, criteria provided, single submitter	clinical testing	Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	Oct 26, 2023	The p.Phe305ProfsX27 in MYBPC3 has been reported in >20 individuals with hypertrophic cardiomyopathy (HCM) and segregated with >10 affected relatives from >10 families (Olivotto 2008 PMID: 18533079, Millat 2010 PMID: 20800588, Marsiglia 2013 PMID: 24093860, Calore 2015 PMID: 25740977, LMM Data). This variant has also been reported by other clinical laboratories in ClinVar (Variation ID 42801). It has been identified in 0.002% (1/67564) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org, v.3.1.2). This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 305 and leads to a premature termination codon 27 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss of function of the MYBPC3 gene is an established disease mechanism in autosomal dominant HCM. In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant HCM. ACMG/AMP Criteria applied: PS4, PP1_Strong, PM2_Supporting, PVS1. -
Pathogenic, criteria provided, single submitter	research	Agnes Ginges Centre for Molecular Cardiology, Centenary Institute	Jan 20, 2017	The MYBPC3 Phe305Profs27 has been previously reported in mulitple HCM patients (Calore C, et al., 2015; Marsiglia JD, et al., 2013; Teirlinck CH, et al., 2012; Millat G, et al., 2010, Olivotto I, et al., 2008), and is an established Italian founder (Calore C, et al., 2015). This variant has not identified in the 1000 genomes project (http://www.1000genomes.org/), or in the Exome Aggregation Consortium dataset (http://exac.broadinstitute.org/). Our lab has identified this variant in 2 HCM probands both of which are of Italian descent. 1 proband harbours a second variant (CRYAB 324+5G>T). Familial screening did not reveal a family history of disease or SCD, therefore the significance of the second variant (CRYAB 324+5G>T) is undetermined. Loss of function mutations in MYBPC3 are an established cause of HCM. Therefore, we classify MYBPC3 Phe305Profs27 as "pathogenic". -
Pathogenic, criteria provided, single submitter	clinical testing	Center for Human Genetics, University of Leuven	Oct 31, 2018	- -

Hypertrophic cardiomyopathy 4

Pathogenic:5

Pathogenic, criteria provided, single submitter	clinical testing	Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen	Jan 24, 2024	- -
Pathogenic, no assertion criteria provided	literature only	OMIM	May 01, 2015	- -
Likely pathogenic, criteria provided, single submitter	clinical testing	Laboratory of Genetics and Molecular Cardiology, University of São Paulo	-	- -
Pathogenic, criteria provided, single submitter	clinical testing	Centre for Mendelian Genomics, University Medical Centre Ljubljana	Feb 21, 2019	This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PM2,PP5. -
Pathogenic, criteria provided, single submitter	clinical testing	Victorian Clinical Genetics Services, Murdoch Childrens Research Institute	Jun 24, 2022	Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with hypertrophic cardiomyopathy 4 (HCM; MIM#115197). (I) 0108 - This gene is associated with both recessive and dominant disease. Dominant inheritance is frequently reported in adult onset conditions, however recessive inheritance results in a more severe early onset phenotype (OMIM). (I) 0115 - Variants in this gene are known to have variable expressivity (PMID: 32841044). (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0302 - Variant is present in gnomAD (v3) <0.001 for a dominant condition (1 heterozygote, 0 homozygotes). (SP) 0701 - Other NMD-predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity (ClinVar, DECIPHER). (SP) 0801 - This variant has very strong previous evidence of pathogenicity in unrelated individuals (ClinVar). It has been reported as a founder mutation for HCM in an Italian cohort and was associated to an increased risk of sudden cardiac death (SCD) and aborted SCD events after the fourth decade of life (PMID: 25740977). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign -

not provided

Pathogenic:3

Pathogenic, no assertion criteria provided	clinical testing	Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+	-	- -
Pathogenic, no assertion criteria provided	clinical testing	Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center	-	- -
Pathogenic, criteria provided, single submitter	clinical testing	GeneDx	Sep 11, 2024	Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 18533079, 20800588, 27532257, 28794111, 31513939, 28699631, 33673806, 36788754, 37652022, 36578016, 35208637, 39160446, 38051749, 25740977) -

Cardiomyopathy

Pathogenic:2

Pathogenic, criteria provided, single submitter	clinical testing	CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario	Jul 30, 2021	- -
Pathogenic, criteria provided, single submitter	clinical testing	Women's Health and Genetics/Laboratory Corporation of America, LabCorp	Apr 25, 2022	Variant summary: MYBPC3 c.913_914delTT (p.Phe305ProfsX27) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 233482 control chromosomes (gnomAD). c.913_914delTT has been reported in the literature in multiple individuals affected with Cardiomyopathy (e.g. Calore_2015, Cecconi_2016, De Bortoli_2017). These data indicate that the variant is very likely to be associated with disease. Nine ClinVar submitters (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -

Hypertrophic cardiomyopathy 4;C3715165:Left ventricular noncompaction 10

Pathogenic:1

Pathogenic, criteria provided, single submitter

clinical testing

Fulgent Genetics, Fulgent Genetics

Sep 27, 2021

- -

Primary familial hypertrophic cardiomyopathy

Pathogenic:1

Pathogenic, criteria provided, single submitter

clinical testing

Blueprint Genetics

Aug 14, 2015

- -

Cardiovascular phenotype

Pathogenic:1

Pathogenic, criteria provided, single submitter

clinical testing

Ambry Genetics

May 26, 2023

The c.913_914delTT pathogenic mutation, located in coding exon 11 of the MYBPC3 gene, results from a deletion of two nucleotides at nucleotide positions 913 to 914, causing a translational frameshift with a predicted alternate stop codon (p.F305Pfs*27). This variant has been detected in several individuals from hypertrophic cardiomyopathy cohorts, has shown segregation with disease in families, and has also been reported as an Italian founder mutation (Olivotto I et al. Mayo Clin. Proc., 2008 Jun;83:630-8; Marsiglia JD. Am. Heart J. 2013 Oct;166(4):775-82; Calore C et al. J. Med. Genet., 2015 May;52:338-47; Walsh R et al. Genet. Med., 2017 02;19:192-203). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -

MYBPC3-related disorder

Pathogenic:1

Pathogenic, criteria provided, single submitter

clinical testing

PreventionGenetics, part of Exact Sciences

Jul 06, 2023

The MYBPC3 c.913_914delTT variant is predicted to result in a frameshift and premature protein termination (p.Phe305Profs*27). This variant was reported in numerous individuals with hypertrophic cardiomyopathy (Olivotto et al. 2008. PubMed ID: 18533079; Table S1B, Walsh et al. 2017. PubMed ID: 27532257; Table S1, Robyns et al. 2020. PubMed ID: 31513939), and was considered an Italian founder variant (Calore et al. 2015. PubMed ID: 25740977). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Frameshift variants in MYBPC3 are expected to be pathogenic. This variant is interpreted as pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name

Calibrated prediction

Score

Prediction

Splicing

Name

Calibrated prediction

Score

Prediction

SpliceAI score (max)

0.0

Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

rs397516080

Variant summary

Frequency

Consequence

Scores

Clinical Significance

Conservation

ACMG classification

Transcripts

RefSeq

Ensembl

Frequencies

ClinVar

Submissions by phenotype

Computational scores

Splicing

Publications

LitVar

Other links and lift over